Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10870652
Compounds and methods for modulating bruton's tyrosine kinase
granted -
US 10870632
Process for producing an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material, and cannabis extracts
granted -
US 10869948
Composition of collagen peptide and elastin peptide, method of producing the same and use thereof
granted -
US 10869933
Oligomer-phenothiazine conjugates
granted -
US 10869880
Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor
granted -
US 10869866
Benzathine analogs
granted -
US 10869871
Compositions and methods of modulating short-chain dehydrogenase activity
granted -
EP 3752616
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR GENEDITIERUNG DURCH TARGETING VON FIBRINOGEN-ALPHA
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
US 10874743
IRAK degraders and uses thereof
granted -
US 10874676
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 10875894
Multimeric bicyclic peptide ligands
granted -
US 10876114
Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53
granted -
US 10874609
ß-cyclodextrin-based star-shaped polymer, a preparation method therefor and an integrated unimolecular micelle system for diagnosis and treatment thereof
granted -
US 10874633
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10874649
2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
granted -
US 10874673
Inhibitors of influenza viruses replication
granted -
US 10874709
Conjugate of salicylic acid and peptide
granted -
US 10874748
Intervention for tendinopathy
granted -
US 10875907
Filovirus antibody
granted -
US 10875911
High affinity human antibodies to human angiopoietin-2
granted -
US 10875913
Methods of treatment using activatable anti-EGFR antibodies
granted -
US 10875920
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
granted -
US 10876118
Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
granted -
US 10874092
Humanized skeletal muscle
granted -
US 10874622
Dual assembly nanoparticles
granted -
US 10874610
Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer
granted -
US 10874334
Methods and systems for quantification of blood-brain barrier permeation of glycosylated peptides
granted -
US 10874631
Altertoxin II as a selective inhibitor of Ewing family of tumor cells
granted -
US 10874648
Methods for the administration of certain VMAT2 inhibitors
granted -
US 10874635
Tocotrienol compositions
granted -
US 10874643
5HT agonists for treating disorders
granted -
US 10874638
Methods and compositions for modulating hormone levels
granted -
US 10874659
Iloperidone metabolite for use in the treatment of psychiatric disorders
granted -
US 10874672
Methods for treating Huntington's disease
granted -
US 10874678
Selective high-affinity polydentate ligands and methods of making such
granted -
US 10875855
Inhibitors of influenza viruses replication
granted -
US 10875915
Anti-CXCR5 antibodies and compositions and uses thereof
granted -
US 10874745
Antimicrobial peptides and methods of treating gram-negative pathogens: polar and non-polar face analogs
granted -
US 10874719
Nucleotide phosphate dissipation as a treatment for vascular disorders
granted -
US 10874727
Inducible regulatory t-cell generation for hematopoietic transplants
granted -
US 10875839
Somatostatin modulators and uses thereof
granted -
US 10874840
Preparation comprising exanatide for delivery into a lumen of the intestinal tract
granted -
US 10874768
Drug eluting medical device
granted -
US 10874752
MIBG analogs and uses thereof
granted -
US 10875885
β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment
granted -
US 10875860
Azaindenoisoquinoline compounds and uses thereof
granted -
US 10875903
Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.